A detailed history of Kestra Advisory Services, LLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Kestra Advisory Services, LLC holds 33,050 shares of IBRX stock, worth $103,446. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,050
Previous 34,020 2.85%
Holding current value
$103,446
Previous $215,000 43.26%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.32 - $6.7 $3,220 - $6,499
-970 Reduced 2.85%
33,050 $122,000
Q2 2024

Aug 14, 2024

BUY
$4.82 - $9.15 $5,784 - $10,980
1,200 Added 3.66%
34,020 $215,000
Q1 2024

May 15, 2024

BUY
$3.23 - $6.17 $19,444 - $37,143
6,020 Added 22.46%
32,820 $176,000
Q4 2023

Feb 14, 2024

BUY
$1.25 - $5.21 $4,375 - $18,235
3,500 Added 15.02%
26,800 $134,000
Q3 2023

Nov 09, 2023

SELL
$1.29 - $3.1 $4,386 - $10,540
-3,400 Reduced 12.73%
23,300 $39,000
Q2 2023

Aug 11, 2023

BUY
$1.53 - $6.41 $40,851 - $171,147
26,700 New
26,700 $74,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.25B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Kestra Advisory Services, LLC Portfolio

Follow Kestra Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kestra Advisory Services, LLC with notifications on news.